{
    "clinical_study": {
        "@rank": "26706", 
        "acronym": "onset\u00ae 3", 
        "arm_group": [
            {
                "arm_group_label": "FIAsp and basal insulin + metformin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin."
            }, 
            {
                "arm_group_label": "Basal insulin + metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia, Europe, South America, and the United States of America\n      (USA).\n\n      The aim of the trial is to investigate efficacy and safety of FIAsp in a basal-bolus regimen\n      versus basal insulin therapy, both in combination with metformin in adult subjects with type\n      2 diabetes."
        }, 
        "brief_title": "Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes (diagnosed clinically) for at least 6 months prior to the screening\n             visit (Visit 1)\n\n          -  Current treatment with once daily insulin detemir, insulin glargine or human isophane\n             insulin, NPH for at least 3 months prior to the screening visit (Visit 1)\n\n          -  Current treatment with a) metformin with unchanged dosing for at least 3 months prior\n             to screening (visit 1). The metformin dose must be at least 1000 mg or b) metformin\n             in combination with sulfonylurea (SU) or glinide or Dipeptidyl peptidase-IV\n             inhibitors and/or alpha-glucosidase inhibitors (AGI) with unchanged dosing for at\n             least 3 months prior to screening (visit 1). The metformin dose must be at least 1000\n             mg\n\n          -  HbA1c by central laboratory a) 7.5-9.5% (58 - 80 mmol/mol) (both inclusive) in the\n             metformin group at the screening visit (Visit 1) or b) 7.5-9.0% (58 - 75 mmol/mol)\n             (both inclusive) in the metformin + other oral antidiabetic drug (OAD) (sulphonylurea\n             (SU), glinide, dipeptidyl peptidase-IV (DDP-IV) inhibitors, alpha-glucosidase\n             inhibitors (AGI) combination group at the screening visit (Visit 1)\n\n          -  Body mass index (BMI) equal or less than 40.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Any use of bolus insulin, except short-term use due to intermittent illness (no\n             longer than 14 days of consecutive treatment) and not within 3 months prior to the\n             screening visit (Visit 1)\n\n          -  Use of Glucagon-like peptide-1 (GLP-1) agonists and/or Thiazolidinediones (TZD)\n             within the last 3 months prior to screening (visit 1)\n\n          -  Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the\n             last 12 months) or hypoglycaemic unawareness as judged by the Investigator, or\n             hospitalisation for diabetic ketoacidosis during the previous 6 months prior to\n             screening (Visit 1)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "286", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850615", 
            "org_study_id": "NN1218-4049", 
            "secondary_id": [
                "2012-005583-10", 
                "U1111-1137-6242", 
                "CTRI/2014/01/004289"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "FIAsp and basal insulin + metformin", 
                "description": "Administrated subcutaneously (s.c., under the skin) at each main meal.", 
                "intervention_name": "insulin aspart (FIAsp)", 
                "intervention_type": "Drug", 
                "other_name": "NN1218"
            }, 
            {
                "arm_group_label": [
                    "FIAsp and basal insulin + metformin", 
                    "Basal insulin + metformin"
                ], 
                "description": "Administrated subcutaneously (s.c., under the skin) once daily.", 
                "intervention_name": "basal insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 8, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35211"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35216"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72205"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Ana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92705"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80922"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80909"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33765"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pembroke Pines", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33028"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Council Bluffs", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "51503"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70121"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20852"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49009"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89101"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11229"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asheboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27203"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Downingtown", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19335-2620"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reading", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19606"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605-4254"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29651"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77025-1669"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sugarland", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77478"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ogden", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84405"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Godoy Cruz", 
                        "country": "Argentina", 
                        "zip": "M5501ARP"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "state": "Andhra Pradesh", 
                        "zip": "500034"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico", 
                        "state": "M\u00e9xico, D.F.", 
                        "zip": "03300"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Targu Mures", 
                        "country": "Romania", 
                        "state": "Mures", 
                        "zip": "540142"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novo mesto", 
                        "country": "Slovenia", 
                        "zip": "8000"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "India", 
                "Mexico", 
                "Romania", 
                "Slovenia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "India: Ministry of Health", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Self-measured plasma glucose (SMPG) 7-point profile: Post prandial plasma glucose (PPG), overall 2-hour mean (of breakfast, lunch, main evening meal)", 
                "safety_issue": "No", 
                "time_frame": "After 18 weeks of randomised treatment"
            }, 
            {
                "measure": "Self-measured plasma glucose (SMPG) 7-point profile: Prandial plasma glucose (PG) increment, overall 2-hour mean (of breakfast, lunch, main evening meal)", 
                "safety_issue": "No", 
                "time_frame": "After 18 weeks of randomised treatment"
            }, 
            {
                "measure": "Change from baseline in body weight", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 18"
            }, 
            {
                "measure": "Number of treatment emergent hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-18"
            }, 
            {
                "measure": "Number of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-18"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}